Phase I, Dose-Escalation, Safety, Pharmacokinetic, And Pharmacodynamic Study Of Single-Agent Pf-03758309, An Oral Pak Inhibitor, In Patients With Advanced Solid Tumors.

JOURNAL OF CLINICAL ONCOLOGY(2011)

Cited 5|Views16
No score
Abstract
e13607^ Background: Abnormalities of the Rho family pathway are involved in different steps of malignant transformation and tumor progression. Of the many effector proteins that bind to active Rho ...
More
Translated text
Key words
oral pak inhibitor,pharmacokinetic,pharmacodynamic study,advanced solid tumors,dose-escalation,single-agent
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined